EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieOpen Access · CC BY 4.0

Adjuvant re-irradiation vs. no early re-irradiation of resected recurrent glioblastoma: pooled comparative cohort analysis from two tertiary centers

Christoph Straube iD, Stephanie E Combs, Denise Bernhardt, Jens Gempt, Bernhard Meyer, Claus Zimmer, Friederike Schmidt-Graf, Peter Vajkoczy, Arne Grün, Felix Ehret, Daniel Zips, David Kaul

Journal of Neuro-Oncology · 2024

DOI: 10.1007/s11060-024-04633-2 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Neuro-Oncology, 2024. Verfasst von Christoph Straube und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany. christoph.straube@klinikum-landshut.de. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Neoplasm Recurrence, Local, Re-Irradiation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Technische Universität München.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The optimal management strategy for recurrent glioblastoma (rGBM) remains uncertain, and the impact of re-irradiation (Re-RT) on overall survival (OS) is still a matter of debate. This study included patients who achieved gross total resection (GTR) after a second surgery after recurrence, following the GlioCave criteria.

Methods

Inclusion criteria include being 18 years or older, having histologically confirmed locally recurrent IDHwt or IDH unknown GBM, achieving MRI-proven GTR after the second surgery, having a Karnofsky performance status of at least 60% after the second surgery, having a minimum interval of 6 months between the first radiotherapy and the second surgery, and a maximum of 8 weeks from second surgery to the start of Re-RT.

Results

A total of 44 patients have met the inclusion criteria. The median OS after the second surgery was 14 months. All patients underwent standard treatment after initial diagnosis, including maximum safe resection, adjuvant radiochemotherapy and adjuvant chemotherapy. Re-RT did not significantly impact OS. However, MGMT promoter methylation status and a longer interval (> 12 months) between treatments were associated with better OS. Multivariate analysis revealed the MGMT status as the only significant predictor of OS.

Conclusion

Factors such as MGMT promoter methylation status and treatment interval play crucial roles in determining patient outcomes after second surgery. Personalized treatment strategies should consider these factors to optimize the management of rGBM. Prospective research is needed to define the value of re-RT after second surgery and to inform decision making in this situation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsNeoplasm Recurrence, LocalRe-IrradiationHumansMaleFemaleMiddle AgedAgedAdultCohort StudiesRadiotherapy, AdjuvantTertiary Care CentersDNA Modification MethylasesDNA Repair EnzymesTumor Suppressor Proteins

Stichwörter der Autor:innen

2nd surgeryAdjuvant radiotherapyCohort studyGTRGlioblastomaGross total resectionRe-irradiationRecurrence

Substanzen

DNA Modification MethylasesDNA Repair EnzymesTumor Suppressor Proteins

Autor:innen und Institutionen

  • Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany. christoph.straube@klinikum-landshut.de.
  • Department of Radiation Oncology and Radiotherapy, Klinikum Landshut, Landshut, Germany. christoph.straube@klinikum-landshut.de.
  • Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
  • Department of Neurosurgery, University Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Neurosurgery, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
  • Department of Neuroradiology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.

ORCID-Profile: Christoph Straube

Förderung

  • Technische Universität München

Zitieren

APA

Straube, C., Combs, S. E., Bernhardt, D., Gempt, J., Meyer, B., Zimmer, C., Schmidt-Graf, F., Vajkoczy, P., Grün, A., Ehret, F., Zips, D., & Kaul, D. (2024). Adjuvant re-irradiation vs. no early re-irradiation of resected recurrent glioblastoma: pooled comparative cohort analysis from two tertiary centers. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-024-04633-2

Vancouver

Straube C, Combs SE, Bernhardt D, Gempt J, Meyer B, Zimmer C, et al. Adjuvant re-irradiation vs. no early re-irradiation of resected recurrent glioblastoma: pooled comparative cohort analysis from two tertiary centers. Journal of Neuro-Oncology. 2024. doi:10.1007/s11060-024-04633-2

BibTeX
@article{Straube2024,
  author = {Straube, Christoph and Combs, Stephanie E and Bernhardt, Denise and Gempt, Jens and Meyer, Bernhard and Zimmer, Claus and Schmidt-Graf, Friederike and Vajkoczy, Peter and Grün, Arne and Ehret, Felix and Zips, Daniel and Kaul, David},
  title = {Adjuvant re-irradiation vs. no early re-irradiation of resected recurrent glioblastoma: pooled comparative cohort analysis from two tertiary centers},
  journal = {Journal of Neuro-Oncology},
  year = {2024},
  doi = {10.1007/s11060-024-04633-2}
}
Kostenlos starten →